Ground Zero Pharmaceuticals, Inc. (GZP) Announces Expansion of Oncology Programs for Its Clients

IRVINE, Calif., Oct. 27, 2011 /PRNewswire/ -- GZP is announcing expansion of its client oncology programs, from strategic and regulatory consulting through product development and clinical trial execution, of pharmaceutical and biological therapies.  These include treatment vaccines, somatic cell and gene therapies, and novel small molecules.  Senior associates with oncology expertise in nonclinical, manufacturing, and clinical development provide clients with hands-on guidance throughout the FDA regulatory review process.  Firms in the US, Europe and Australia are actively working with GZP, in Phase 1 through Phase 3 clinical trials.

Dr. Evan B. Siegel, GZP's CEO, will be at BioEurope in Dusseldorf and BioMalaysia in Kuala Lumpur, and will be pleased to meet with interested parties during either meeting's formal partnering or by individual arrangement.

In 2011, GZP increased its global client base at all development phases across therapeutic areas such as oncology and neurological disease.  The firm created and submitted several INDs and SPAs and facilitated many pre-IND and mid-phase meetings with the FDA leading to rapid movement of client programs.  GZP believes that early, frequent, and creative FDA communication leads to more successful product development and attracts investors in today's difficult financial climate.

According to Evan Siegel, "We are pleased that the disappointing recovery from the global financial crisis has not diminished the entry of new intellectual property into the biotechnology and pharmaceutical space.  Our clients are determined to be successful and we are honored to provide support towards that end.  The expansion of our business is attributable to their trust in GZP, due to the excellence of our team which maintains an integrated and client-specific approach to deliver the highest quality services."

Based in Irvine, Ground Zero Pharmaceuticals, Inc. is a regulatory affairs, product development, and clinical consulting firm providing strategic and tactical services to the pharmaceutical, biotechnology and medical device industries.  These include regulatory representation and submissions, medical consulting and monitoring, preclinical planning, auditing of clinical, nonclinical and manufacturing sites, medical writing, chemistry, manufacturing and controls consulting, clinical trial execution, data management, biostatistics, and project management.  GZP has resources throughout the US, Canada, Australia and Europe, and a wholly owned subsidiary in Brisbane and Melbourne, Australia.

For further information please contact Ms. Tisha Templeton, Senior Vice President, Finance and Operations, Ground Zero Pharmaceuticals, Inc., +1-949-419-6136, fax, +1-949-861-9797, [email protected].

Web Site: http://www.groundzerous.com

SOURCE Ground Zero Pharmaceuticals, Inc.